<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124236</url>
  </required_header>
  <id_info>
    <org_study_id>410.000.146</org_study_id>
    <nct_id>NCT05124236</nct_id>
  </id_info>
  <brief_title>Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases</brief_title>
  <acronym>PREOP-2</acronym>
  <official_title>A Multicenter Prospective, Interventional, Randomized Trial of Preoperative Radiosurgery Compared With Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susanne Rogers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kantonsspital Aarau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research question is whether a single fraction of preoperative radiosurgery can reduce&#xD;
      the incidence of leptomeningeal disease 12 months following resection of a brain metastasis&#xD;
      (BM) as compared with 5 fractions of postoperative stereotactic radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurosurgical resection of a brain metastasis in patients with a diagnosis of cancer may be&#xD;
      indicated however the recurrence rate approximates 50% and adjuvant radiotherapy is standard.&#xD;
      Single fraction postoperative stereotactic radiosurgery (SRS) has been widely adopted as a&#xD;
      standard therapy as it achieves equivalent survival and prevents loss of neurocognitive&#xD;
      function as compared with whole brain radiotherapy and improves cavity local control rates as&#xD;
      compared with observation. Hypofractionated stereotactic radiotherapy in 3 to 5 fractions&#xD;
      (hfSRT) is also used in the postoperative setting.&#xD;
&#xD;
      Nodular leptomeningeal disease (nLMD) is a recognised pattern of failure after postoperative&#xD;
      SRS and hfSRT. A 16.9% incidence of nodular LMD was seen after surgery and a similar&#xD;
      incidence of 11%-28%is reported following postoperative SRS in retrospective series. These&#xD;
      data suggest that postoperative SRS/hfSRT have no significant effect on the development of&#xD;
      LMD following surgery.&#xD;
&#xD;
      The incidence of LMD following single fraction preoperative SRS is only 6.1% according to the&#xD;
      largest retrospective series. Preoperative SRS takes advantage of the easier delineation of&#xD;
      an intact BM and sterilizes tumor cells disseminated at surgery. Side effects are minimized&#xD;
      by a smaller planning margin, a dose reduction and resection of the irradiated volume. In&#xD;
      addition, there is no delay to systemic therapy due to wound healing/complications.&#xD;
      Furthermore, a single fraction offers patient convenience.&#xD;
&#xD;
      This trial will randomise and compare intracranial outcomes between single fraction&#xD;
      preoperative SRS and 5 fraction postoperative hFSRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leptomeningeal disease</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>Incidence (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control of the surgical cavity</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>No evidence of tumour recurrence on contrsat-enhanced MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant brain failure</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>New brain metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radionecrosis</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>Adverse radiation effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>3,6,12 months after intervention</time_frame>
    <description>EORTC questionnaire core questionnaire QLQ30 (1-4, low scores reflect better QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>3,6,12 months after intervention</time_frame>
    <description>EORTC questionnaire brain module BN 20 (1-4, low scores reflect better QoL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <arm_group>
    <arm_group_label>Preoperative radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The interventional arm is single fraction preoperative radiosurgery to a brain metastasis identified for neurosurgical resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative hypofractionated stereotactic radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active comparator arm is the standard of care of postoperative hypofractionated stereotactic radiotherapy to the surgical cavity in 5 fractions following resection of the brain metastasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>preoperative radiosurgery</intervention_name>
    <description>single fraction radiosurgery</description>
    <arm_group_label>Preoperative radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>postoperative hypofractionated stereotactic radiotherapy</intervention_name>
    <description>5 fraction stereotactic radiotherapy /fractionated radiosurgery</description>
    <arm_group_label>Postoperative hypofractionated stereotactic radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Age ≥18&#xD;
&#xD;
          4. Karnofsky performance status ≥60&#xD;
&#xD;
          5. Histological diagnosis of a malignant primary or metastatic tumour&#xD;
&#xD;
          6. Ability to take steroids&#xD;
&#xD;
          7. No contraindication to magnetic resonance imaging (MRI)&#xD;
&#xD;
          8. MRI-diagnosis of a clearly demarcated contrast-enhancing brain metastasis up to 4.0 cm&#xD;
             diameter indicated for neurosurgical resection (tumorboard decision). Up to 3 other&#xD;
             brain metastases suitable for primary radiosurgery/ stereotactic radiotherapy&#xD;
&#xD;
          9. Survival estimated by primary clinician &gt; 12 months&#xD;
&#xD;
         10. Platelet count &gt; 100/ml, INR &lt; 1.3, Hb &gt; 7.5 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radiosensitive histology: germ cell tumour, lymphoma, multiple myeloma&#xD;
&#xD;
          2. &gt;10 mm midline shift, effacement of the 4th ventricle or other sign of raised&#xD;
             intracranial pressure requiring urgent decompressive surgery&#xD;
&#xD;
          3. More than 4 brain metastases or the diameter of the metastasis for resection &gt;4.0 cm.&#xD;
&#xD;
          4. More than 1 metastasis requiring resection&#xD;
&#xD;
          5. Leptomeningeal disease in the CSF or on MRI (unless localized and can be irradiated&#xD;
             then resected with the metastasis)&#xD;
&#xD;
          6. Prior radiation to the brain (SRS/SRT to lesion to be resected and /or WBRT)&#xD;
&#xD;
          7. Prior resection of a primary or secondary brain tumor&#xD;
&#xD;
          8. Prior diagnosis of a non-meningioma brain tumor&#xD;
&#xD;
          9. Prior radionuclide therapy within 30 days&#xD;
&#xD;
         10. Prior anti-VEGF therapy within 6 weeks&#xD;
&#xD;
         11. Unable to tolerate radiosurgery immobilization and treatment&#xD;
&#xD;
         12. Inability to give informed consent&#xD;
&#xD;
         13. Pregnancy or lactation&#xD;
&#xD;
         14. Females of reproductive potential not willing to use effective contraception for at&#xD;
             least 6 months after radiotherapy&#xD;
&#xD;
         15. Males of reproductive potential not effective contraception for 3 months after&#xD;
             radiotherapy&#xD;
&#xD;
         16. Lack of likely compliance with protocol and follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Susanne J Rogers, MD PhD</last_name>
      <phone>0041628385726</phone>
      <email>susanne.rogers@ksa.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sonja Schwenne</last_name>
      <phone>0041628386259</phone>
      <email>sonja.schwenne@ksa.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Aarau</investigator_affiliation>
    <investigator_full_name>Susanne Rogers</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

